Differential expression of miRNAs from extracellular vesicles in chronic graft-versus-host disease: A preliminary study.

Autor:	Łacina P; Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland., Crossland RE; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, United Kingdom., Wielińska J; Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland., Czyż A; Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland., Szeremet A; Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland., Ussowicz M; Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Poland., Wróbel T; Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland., Dickinson AM; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, United Kingdom., Bogunia-Kubik K; Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Jazyk:	angličtina
Zdroj:	Advances in clinical and experimental medicine : official organ Wroclaw Medical University [Adv Clin Exp Med] 2023 May; Vol. 32 (5), pp. 539-544.
DOI:	10.17219/acem/155373
Abstrakt:	Background: Chronic graft-versus-host disease (cGvHD) is a complex disorder that typically manifests after allogeneic hematopoietic stem cell transplantation (HSCT). It is a major cause of non-relapse mortality, which makes finding biomarkers associated with its occurrence a priority. Recent studies increasingly indicate that microRNAs (miRNAs, short regulatory RNA molecules) can be used as biomarkers of various disorders. They can circulate in patients' bodies encapsulated within extracellular vesicles (EVs). Objectives: To identify miRNAs associated with the occurrence of cGvHD in EVs isolated from the plasma of patients after allogeneic HSCT. Material and Methods: We performed global miRNA expression profiling in a pilot cohort of 3 cGvHD cases and 4 non-cGvHD patients without disease symptoms 90 days after the transplantation (control group). Results: The 2 groups were naturally clustered according to their miRNA profiles using unsupervised hierarchical clustering analysis. We identified 3 miRNAs that were differentially expressed in the cGvHD patients compared to the non-cGvHD patients. The levels of hsa-miR-630 and hsa-miR-374b-5p were lower in the cGvHD patients: 4.1-fold (p = 0.002) and 2.7-fold (p = 0.044), respectively. In contrast, the levels of hsa-miR-29c-3p were 5.8-fold higher (p = 0.004). Conclusions: Our results suggest that miRNA profiles from plasma EVs may act as markers of cGvHD onset.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu